Effect of PP-01 on Cannabis Withdrawal Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a medication called PP-01 to see if it can help people with severe cannabis use disorder feel better when they quit using cannabis. The study involves 225 participants and aims to reduce the uncomfortable withdrawal symptoms they experience.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on stable psychotropic medication for at least 3 months, you may be included at the investigator's discretion.
What safety data exists for the treatment known as PP-01?
The safety of treatments in phase I clinical trials, which often include healthy volunteers, is generally monitored for adverse events (unwanted effects). A study analyzing 142 phase I trials found that adverse events do occur, but the frequency and seriousness can vary. It's important to note that safety reporting in clinical trials can sometimes be inconsistent, and efforts are being made to improve the standardization and thoroughness of safety data collection.12345
How does the drug PP-01 differ from other treatments for this condition?
Who Is on the Research Team?
Jay Constantine, MD
Principal Investigator
PleoPharma, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive study medication for 34 days to mitigate cannabis withdrawal symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PP-01
Find a Clinic Near You
Who Is Running the Clinical Trial?
PleoPharma, Inc.
Lead Sponsor